Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial--the NeuroMorfeo trial.
BACKGROUND
Many studies have attempted to determine the "best" anaesthetic technique for neurosurgical procedures in patients without intracranial hypertension. So far, no study comparing intravenous (IA) with volatile-based neuroanaesthesia (VA) has been able to demonstrate major outcome differences nor a superiority of one of the two strategies in patients undergoing elective supratentorial neurosurgery. Therefore, current practice varies and includes the use of either volatile or intravenous anaesthetics in addition to narcotics. Actually the choice of the anaesthesiological strategy depends only on the anaesthetists' preferences or institutional policies. This trial, named NeuroMorfeo, aims to assess the equivalence between volatile and intravenous anaesthetics for neurosurgical procedures.


METHODS
NeuroMorfeo is a multicenter, randomized, open label, controlled trial, based on an equivalence design. Patients aged between 18 and 75 years, scheduled for elective craniotomy for supratentorial lesion without signs of intracranial hypertension, in good physical state (ASA I-III) and Glasgow Coma Scale (GCS) equal to 15, are randomly assigned to one of three anaesthesiological strategies (two VA arms, sevoflurane + fentanyl or sevoflurane + remifentanil, and one IA, propofol + remifentanil). The equivalence between intravenous and volatile-based neuroanaesthesia will be evaluated by comparing the intervals required to reach, after anaesthesia discontinuation, a modified Aldrete score > or = 9 (primary end-point). Two statistical comparisons have been planned: 1) sevoflurane + fentanyl vs. propofol + remifentanil; 2) sevoflurane + remifentanil vs. propofol + remifentanil. Secondary end-points include: an assessment of neurovegetative stress based on (a) measurement of urinary catecholamines and plasma and urinary cortisol and (b) estimate of sympathetic/parasympathetic balance by power spectrum analyses of electrocardiographic tracings recorded during anaesthesia; intraoperative adverse events; evaluation of surgical field; postoperative adverse events; patient's satisfaction and analysis of costs. 411 patients will be recruited in 14 Italian centers during an 18-month period.


CONCLUSIONS
We presented the development phase of this anaesthesiological on-going trial. The recruitment started December 4th, 2007 and up to 4th, December 2008, 314 patients have been enrolled.
Neuroanaesthesia and Neurointensive Care Unit, Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital, Monza, Milano, Italy. g.citerio@hsgerardo.org
Giuseppe
G
Citerio
Maria Grazia
MG
Franzosi
Roberto
R
Latini
Serge
S
Masson
Simona
S
Barlera
Stefano
S
Guzzetti
Antonio
A
Pesenti
D000759:Adjuvants, Anesthesia; D000758:Anesthesia / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D018685:Anesthetics, Inhalation / Q000009:adverse effects / Q000191:economics; D018686:Anesthetics, Intravenous / Q000009:adverse effects / Q000191:economics; D003362:Cost-Benefit Analysis; D003399:Craniotomy; D016527:Drug Costs; D017558:Elective Surgical Procedures; D005283:Fentanyl; D006801:Humans; D007558:Italy; D008738:Methyl Ethers / Q000009:adverse effects / Q000191:economics; D017060:Patient Satisfaction; D010880:Piperidines; D015742:Propofol / Q000009:adverse effects / Q000191:economics; D000077208:Remifentanil; D012107:Research Design; D000077149:Sevoflurane; D016896:Treatment Outcome
D000759:Adjuvants, Anesthesia; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D008738:Methyl Ethers; D010880:Piperidines; D000077149:Sevoflurane; D000077208:Remifentanil; D005283:Fentanyl; D015742:Propofol